Ibrutinib suppression of chronic lymphocytic leukemia endures in second year

The targeted therapy ibrutinib continues to stifle relapsed or resistant chronic lymphocytic leukemia for patients in an extended clinical trial while treatment side effects decline in frequency and severity over time, researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news